In a nutshell This study examined whether it is safe to switch from intravenous to subcutaneous rituximab (Rituxan) during first-line treatment of non-Hodgkin's lymphoma (NHL). The authors concluded that subcutaneous rituximab was safe and effective, and improved quality of life for patients. Some background Rituximab is a standard...
Read MorePerformance status -3 – Symptomatic, 50 in bed Posts on Medivizor
Looking for patients with relapsed or unresponsive acute myeloid leukemia to test a new targeted therapy drug
In a nutshell This trial is examining the effectiveness of crenolanib after salvage chemotherapy for relapsed or unresponsive acute myeloid leukemia (AML) with FLT3 activating mutations. The main outcome would be survival without complications from leukemia 3 years after the treatment has finished. The details AML is a type of blood...
Read MoreSearching for newly diagnosed patients with B-lineage acute lymphoblastic leukemia to participate in a randomized immunotherapy trial
In a nutshell This phase 3 clinical trial will test the effectiveness of blinatumomab (Blincyto) with chemotherapy versus chemotherapy alone in treating patients with newly diagnosed B lineage acute lymphoblastic leukemia (ALL) that is BCR-ABL negative. The primary outcome will be measured by the overall survival. The details Blinatumomab is...
Read More
